Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MF59-Adjuvanted H5N1 Influenza Vaccine
NCT00311480Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of inactivated Vero cell based whole virus influenza A/H5N1, sponsored by Novartis. Started Mar 2006; status: completed.
02
Drugs
inactivated Vero cell based whole virus influenza A/H5N1
Beyond the preview
Go deeper on NCT00311480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311480.